US 12,077,537 B2
Capsid inhibitors for the treatment of HIV
Chienhung Chou, Dublin, CA (US); Scott E. Lazerwith, San Francisco, CA (US); John O. Link, San Francisco, CA (US); Scott D. Schroeder, Union City, CA (US); Winston C. Tse, Redwood City, CA (US); and Jennifer R. Zhang, Union City, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Feb. 15, 2023, as Appl. No. 18/110,126.
Application 18/110,126 is a continuation of application No. 17/357,376, filed on Jun. 24, 2021, granted, now 11,680,064.
Claims priority of provisional application 63/044,086, filed on Jun. 25, 2020.
Prior Publication US 2023/0312567 A1, Oct. 5, 2023
Int. Cl. C07D 513/06 (2006.01); A61K 31/4365 (2006.01); A61K 31/437 (2006.01); A61K 45/06 (2006.01); C07D 403/12 (2006.01); C07D 471/04 (2006.01); C07D 471/06 (2006.01); C07D 498/04 (2006.01); C07D 513/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 45/06 (2013.01); C07D 403/12 (2013.01); C07D 498/04 (2013.01); C07D 513/04 (2013.01); C07D 519/00 (2013.01)] 8 Claims
 
1. A compound that is selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.